Korro Bio (NASDAQ:KRRO) Major Shareholder Mohamad Makhzoumi Purchases 207,100 Shares

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Mohamad Makhzoumi bought 207,100 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the transaction, the insider owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This represents a 18.99% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Price Performance

Shares of KRRO stock traded up $1.45 on Friday, hitting $12.95. 552,892 shares of the stock traded hands, compared to its average volume of 237,193. The company’s fifty day moving average is $10.90 and its 200 day moving average is $20.23. Korro Bio, Inc. has a 1-year low of $5.20 and a 1-year high of $55.89. The company has a market capitalization of $121.97 million, a PE ratio of -1.38 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.The business had revenue of $1.29 million during the quarter, compared to analyst estimates of $0.43 million. As a group, equities research analysts expect that Korro Bio, Inc. will post -9.52 EPS for the current year.

Trending Headlines about Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KRRO. Nantahala Capital Management LLC bought a new stake in shares of Korro Bio during the fourth quarter valued at approximately $4,806,000. TCG Crossover Management LLC bought a new position in Korro Bio in the 3rd quarter worth approximately $19,937,000. Vanguard Group Inc. increased its position in Korro Bio by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock valued at $18,948,000 after acquiring an additional 8,921 shares during the period. Polar Capital Holdings Plc raised its stake in Korro Bio by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock valued at $12,676,000 after acquiring an additional 14,694 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after acquiring an additional 4,650 shares in the last quarter. Institutional investors own 13.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KRRO. Wall Street Zen downgraded shares of Korro Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, January 9th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Finally, Piper Sandler downgraded Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 price target on the stock. in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio has a consensus rating of “Moderate Buy” and an average target price of $44.50.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.